Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of PTT-121
Sponsor: Pyrotech Therapeutics, Inc.
Summary
This is a Phase I, single-center, randomized, double-blind, placebo-controlled SAD/MAD study to evaluate safety, tolerability, and PK of Intravenously Administered PTT-121 in healthy Chinese adults.
Official title: A Phase I, Single-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenously Administered PTT-121 After Single and Multiple Ascending Doses in Healthy Chinese Subjects
Key Details
Gender
All
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
84
Start Date
2026-08-31
Completion Date
2028-02-28
Last Updated
2026-08-17
Healthy Volunteers
Yes
Conditions
Interventions
PTT-121
PTT-121 will be administered intravenously
PTT-121 placebo
Matching placebo identical to PTT-121 formulation but without the active pharmaceutical ingredient
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China